CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026
CareDx presented new AlloSure Kidney data at ASN Kidney Week 2026, headlined by a KOAR registry analysis showing dd-cfDNA levels ≥1% were linked to a nearly 3-fold higher risk of allograft loss or ≥30% kidney function decline in patients with borderline rejection or TCMR (P=0.002). In a 332-patient randomized trial run by Paris Transplant Group, dd-cfDNA-guided monitoring cut biopsies by 49% with similar safety and kidney-function outcomes versus surveillance biopsy.
Key figures
- Drug Name
- AlloSure Kidney (dd-cfDNA)
- Risk hazard
- nearly 3-fold higher risk of allograft loss or ≥30% kidney function decline at AlloSure ≥1% (P=0.002)
- Validation auc
- 0.833 under Banff 2024 criteria
- Biopsy reduction
- 49% fewer biopsies with dd-cfDNA monitoring (IRR 0.51; P<0.001)
- Validation biopsies
- 6827
- Koar cohort patients
- 131
- Randomized trial patients
- 332
- Validation cohort patients
- 4976
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.